debt_leverage_profile
0.03x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Minimal direct debt sensitivity; company is pre-revenue clinical-stage with equity-financed operations, rate hikes primarily increase cost of future capital raises
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Oncolytic virus vector manufacturing (limited CDMO capacity globally); specialized cell culture reagents sourced from few qualified suppliers
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue; clinical trials in early stage, currency devaluation exposure is negligible at this time
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in US; no top-three international revenue markets exist; sovereign currency devaluation risk is effectively zero currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CDMO dependency for clostridia-based vector manufacturing likely exceeds 30% of operational input cost and is non-substitutable short-term
Inferred
Agent_Inference
business_model_type_primary
Cloud termination would cause administrative disruption but not clinical failure; core IP and manufacturing are physical, not cloud-dependent
Inferred
Agent_Inference
business_model_type_secondary
Preclinical/clinical-stage biotech; secondary model involves licensing or partnership deals for platform technology
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company is a biotech with biological manufacturing dependencies, not software-API dependent
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is grant/milestone/partnership-based; no token issuance; Howey Test not applicable, risk index effectively zero
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; clinical trial patient data requires IRB/FDA compliance but commercial data processing footprint is minimal
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; company holds no market power, operates in niche oncology space with multiple competing modalities
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional/grant-based; no recurring subscription revenue; milestone payments and grants dominate current cash inflows
Inferred
Agent_Inference
monetization_vector
Grant funding, NIH/DoD contracts, and potential licensing milestones; no product revenue yet
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture exists; future pricing will be oncology drug market-rate, likely $100K–$500K+ per treatment course
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if clinical success achieved; orphan oncology drugs command premium pricing with limited payer pushback
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margins of 70–85% if commercialized as drug therapy, consistent with specialty biologics sector benchmarks
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; proprietary biological platform with patent protection limits unauthorized use
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is heavily sublinear to headcount; clinical-stage milestones do not require proportional headcount scaling
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth driven by CDMO manufacturing scale-up and clinical trial enrollment costs, not headcount
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network exists
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics depend on hospital/oncology center adoption; patient acquisition driven by KOL engagement and clinical evidence
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value is derived from clinical efficacy data and IP, not user-base scale
Inferred
Agent_Inference
asset_efficiency_ratio
-62.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate recession resistance; oncology treatment demand is inelastic but funding for clinical-stage biotechs tightens in downturns
Inferred
Agent_Inference
customer_segment_primary
Government/DoD grant agencies and potential pharma licensing partners as primary near-term revenue sources
Inferred
Agent_Inference
customer_segment_secondary
Hospital oncology centers and cancer treatment networks as eventual end-market customers post-commercialization
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated primarily to clinical trials and CDMO manufacturing contracts; no legacy infrastructure reallocation dynamic present
Inferred
Agent_Inference
sec_cik
0000894158
High
SEC-EDGAR
ticker
TOVX
High
SEC-EDGAR